Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Accumulated Expenses (2016 - 2025)

Amicus Therapeutics' Accumulated Expenses history spans 13 years, with the latest figure at $200.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 57.47% year-over-year to $200.5 million, compared with a TTM value of $200.5 million through Dec 2025, up 57.47%, and an annual FY2025 reading of $200.5 million, up 57.47% over the prior year.
  • Accumulated Expenses for Q4 2025 was $200.5 million at Amicus Therapeutics, up from $171.2 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $200.5 million in Q4 2025, with the low at $57.2 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $118.8 million, with a median of $125.1 million recorded in 2022.
  • Year-over-year, Accumulated Expenses dropped 19.13% in 2021 and then soared 72.85% in 2022.
  • Tracing FOLD's Accumulated Expenses over 5 years: stood at $98.2 million in 2021, then dropped by 4.6% to $93.6 million in 2022, then surged by 54.05% to $144.2 million in 2023, then decreased by 11.75% to $127.3 million in 2024, then skyrocketed by 57.47% to $200.5 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Accumulated Expenses are $200.5 million (Q4 2025), $171.2 million (Q3 2025), and $145.1 million (Q2 2025).